Vishesh Agarwal, M.D.

Our Experts

Back to all Experts
Vishesh Agarwal, M.D.

Vishesh Agarwal, M.D.

Vice Chair of Department of Psychiatry

Expertise & Research Interests

  • Evidence Based Care
  • Smoking Cessation
  • Behavioral Addictions
  • Inpatient Psychiatrist
  • Addiction Psychiatry
  • Psychiatry
  • Crisis Intervention
  • Risk Assessment


  • M.D., Gauhati Medical College

Vishesh Agarwal, M.D.

Vice Chair of Department of Psychiatry

Dr. Vishesh Agarwal is an inpatient psychiatrist with board certification in general adult and addiction psychiatry. He oversees ChristianaCare's state-of-the-art behavioral health unit along with the embedded crisis units in the health system's emergency departments, and serves as a consult liaison for medical floors. He is skilled in psychiatric epidemiology, population health, and health care management as it relates to behavior health. His research on substance use disorders and behavioral addictions is frequently published in peer-reviewed medical journals.


of 09


Downloadable Images and Links
Media Appearances

Too much smartphone time may invite host of health woes

2019-07-19 , News24
With most people never far from their cellphones, new research on college students finds that “problematic” use is tied to a variety of mental health problems, as well as lower grades and more sexual partners.

Krokodil: ‘Zombie Drug’ Scare Hits U.S.

2014-03-07 , Psychiatric News: The American Psychiatric Association (APA)
Krokodil, the so called “flesh-eating zombie drug,” is the newest addictive drug to reportedly hit the United States. Scary photographs showing deep wounds on people’s extremities abound on the Internet. Television news programs have given us a number of interviews with emergency room physicians who have alerted the public on the dangers of this latest drug menace. How much of this is true, and how much is simply hype?
Selected Papers and Publications

Gambling in patients with major depressive disorder is associated with an elevated risk of Suicide: Insights from 12-years of Nationwide inpatient sample data

Addictive Behaviors
There is a frequent occurrence of gambling disorder (GD) in patients with major depressive disorder (MDD). Psychiatric comorbidities can present more severely in patients diagnosed with pathological gambling. There is limited information on symptom trends in MDD patients with GD, particularly in association with suicidality.

Simple Schizophrenia Remains a Complicated Diagnosis Case Report and Literature Review

The Journal of Nervous and Mental Disease
The diagnosis of simple schizophrenia has been challenged and criticized since it was first described by Otto Diem in 1903. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), released by the American Psychiatric Association in May 2013, classified it as a condition for further study with the name “attenuated psychosis syndrome.” This clinical condition has undergone several revisions with each edition of the DSM.

Art therapy in a patient with bipolor disorder: pictures speak more than a thousand words

Psychiatric Times
Art therapy is defined by the American Art Therapy Association as "a mental health profession in which clients, facilitated by the art therapist, use art media, the creative process, and the resulting artwork to explore their feelings, reconcile emotional conflicts, foster self awareness, manage behavior and addictions, develop social skills, improve reality orientation, reduce anxiety, and increase self-esteem

Fentanyl-Laced Heroin Deaths on the Rise Once Again

AVENTURA, Florida ― The potentially deadly practice of lacing heroin with the synthetic opioid analgesic fentanyl appears to have made a comeback, with almost 60 individuals dying because of fentanyl overdose in Philadelphia in the first half of 2014 alone.

Selective Effect s of Individual Antipsychotic Cotreatments on Cardiometabolic and Hormonal Risk Status: Results from a Systematic Review and Meta-analysis

Schizophrenia Bulletin
Background: Antipsychotic cotreatment (APCT), frequent in clinical care, has been criticized for lack of supportive evidence and additive adverse effects, but improved side effects have also been described. METHODOLOGY: Metaanalysis of randomized placebo controlled trials (RPCTs) of APCT vs. placebo in schizophrenia.

Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics

Molecular Psychiatry
Few controlled trials compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We conducted a systematic review/meta-analysis of randomized trials, lasting ⩾6 months comparing SGAs with FGAs in schizophrenia. Primary outcome was study-defined relapse; secondary outcomes included relapse at 3, 6 and 12 months; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability.

Ayurvedic medicine for schizophrenia

Cochrane Library
Ayurvedic medicine has been used to treat mental health problems since1000 BC.
To review effects of Ayurvedic medicine or treatments for schizophrenia.
Search methods
We searched the Cochrane Schizophrenia Group Trials Register (March 2007) and AMED (March 2007), inspected references of all identified studies and contacted the first author of each included study.
External Service and Affiliations
  • American Psychiatry Association : Member
  • Indo American Psychiatric Association : Member
  • American Society of Addiction Medicine : Member
  • American Society of Clinical Psychopharmacology : Member